J INTS BIO, AACR 2024 - 'JIN-A02', a Novel Oral 4th Generation EGFR TKI, showing Clinical Benefits in the Ongoing Phase 1 Study
07.08.2025 - 18:04:49 | prnewswire.co.uk
View original content:https://www.prnewswire.co.uk/news-releases/j-ints-bio-aacr-2024--jin-a02-a-novel-oral-4th-generation-egfr-tki-showing-clinical-benefits-in-the-ongoing-phase-1-study-302114160.html
en | boerse | 67979745 |
